TickerFacts.

CervoMed Inc. (CRVO): Revenue

Annual figures by period end, from SEC filings.

$4.01M
Year ended 2025-12-31
$331.3K
Trailing 12 months to 2026-06-30
$9.74M2010-12-31: $40.2K2011-12-31: $570.5K2012-12-31: $374.5K2013-12-31: $71.7K2022-12-31: $02023-12-31: $7.14M2024-12-31: $9.74M2025-12-31: $4.01M$4.01M
2010-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$4.01M-58.9%2026-03-13, From 2025-01-01
2024-12-31$9.74M+36.3%2026-03-13, From 2024-01-01
2023-12-31$7.14Mn/a2025-03-17, From 2023-01-01
2022-12-31$0n/a2024-03-29, From 2022-01-01
No annual figure between 2013-12-31 and 2022-12-31.
2013-12-31$71.7K-80.9%2014-04-23, From 2013-01-01
2012-12-31$374.5K-34.3%2013-04-24, From 2012-01-01
2011-12-31$570.5Kn/m2013-04-24, From 2011-01-01
2010-12-31$40.2Kn/a2012-05-21, From 2010-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
CervoMed Inc. (CRVO)2025-12-31$4.01M-58.9%
China Pharma Holdings, Inc. (CPHI)2025-12-31$4.14M-8.5%
ProPhase Labs, Inc. (PRPH)2025-12-31$4.34M-35.8%
Marker Therapeutics, Inc. (MRKR)2025-12-31$3.55M-46.2%
Camp4 Therapeutics Corp (CAMP)2025-12-31$3.50M+436.5%
Ensysce Biosciences, Inc. (ENSC)2025-12-31$5.07M-2.8%
TherapeuticsMD, Inc. (TXMD)2025-12-31$3.02M+71.6%
Xenetic Biosciences, Inc. (XBIO)2025-12-31$2.98M+19.0%
Upstream Bio, Inc. (UPB)2025-12-31$2.85M+20.4%

Compare CRVO, CPHI, PRPH, MRKR side by side · Screen every company in Pharmaceutical Preparations ↗